Th2 and Th17-Associated Immunopathology Following SARS-CoV-2 Breakthrough Infection in Spike-Vaccinated ACE2-humanized Mice.

Breakthrough Infection Eosinophil Pulmonary Immunopathology Spike Protein Vaccine Th17 Th2

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
19 Oct 2023
Historique:
pubmed: 31 10 2023
medline: 31 10 2023
entrez: 31 10 2023
Statut: epublish

Résumé

Vaccines have demonstrated remarkable effectiveness in protecting against COVID-19; however, concerns regarding vaccine-associated enhanced respiratory diseases (VAERD) following breakthrough infections have emerged. Spike protein subunit vaccines for SARS-CoV-2 induce VAERD in hamsters, where aluminum adjuvants promote a Th2-biased immune response, leading to increased type 2 pulmonary inflammation in animals with breakthrough infections. To gain a deeper understanding of the potential risks and the underlying mechanisms of VAERD, we immunized ACE2-humanized mice with SARS-CoV-2 Spike protein adjuvanted with aluminum and CpG-ODN. Subsequently, we exposed them to increasing doses of SARS-CoV-2 to establish a breakthrough infection. The vaccine elicited robust neutralizing antibody responses, reduced viral titers, and enhanced host survival. However, following a breakthrough infection, vaccinated animals exhibited severe pulmonary immunopathology, characterized by a significant perivascular infiltration of eosinophils and CD4

Identifiants

pubmed: 37904941
doi: 10.1101/2023.10.18.563016
pmc: PMC10614945
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI151139
Pays : United States

Déclaration de conflit d'intérêts

Conflicts of interest: W.H. receives research support from MegaRobo Technologies Co., Ltd. and A.A. receives sponsored program funding from 3M, which were not related to this study. The other authors claim no conflicts of interest.

Références

PLoS One. 2014 Jun 03;9(6):e98915
pubmed: 24892823
Vaccine. 2022 Jun 9;40(26):3655-3663
pubmed: 35568591
EClinicalMedicine. 2021 Aug 28;40:101117
pubmed: 34476395
Front Immunol. 2023 Feb 24;14:1043109
pubmed: 36911719
J Immunol. 2008 Oct 15;181(8):5490-500
pubmed: 18832706
Mol Biol. 2020;54(6):812-826
pubmed: 32921819
J Virol. 2014 Aug;88(15):8597-614
pubmed: 24850731
Expert Rev Vaccines. 2011 Apr;10(4):499-511
pubmed: 21506647
Cell. 2022 Jul 7;185(14):2434-2451.e17
pubmed: 35764089
PLoS One. 2012;7(4):e35421
pubmed: 22536382
Am J Epidemiol. 1969 Apr;89(4):422-34
pubmed: 4305198
Int Immunopharmacol. 2018 Apr;57:132-138
pubmed: 29482157
Med Hypotheses. 2020 Jul;140:109749
pubmed: 32339777
C R Biol. 2017 Nov - Dec;340(11-12):456-473
pubmed: 29195855
Cell Host Microbe. 2016 Nov 9;20(5):596-605
pubmed: 27923703
Immunity. 2009 Aug 21;31(2):321-30
pubmed: 19682928
Int J Rheum Dis. 2016 Apr;19(4):392-404
pubmed: 25545680
Viruses. 2022 Mar 19;14(3):
pubmed: 35337047
Cochrane Database Syst Rev. 2022 Dec 7;12:CD015477
pubmed: 36473651
Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):14-22
pubmed: 26750756
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Br J Clin Pharmacol. 2021 Mar;87(3):1578-1581
pubmed: 32627226
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
J Virol. 2011 Dec;85(23):12201-15
pubmed: 21937658
Science. 2010 Feb 26;327(5969):1098-102
pubmed: 20185720
J Virol. 2015 Mar;89(6):2995-3007
pubmed: 25520500
J Allergy Clin Immunol. 2020 Jul;146(1):1-7
pubmed: 32344056
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Front Immunol. 2013 Jan 10;3:406
pubmed: 23335921
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793
pubmed: 34043615
Sci Adv. 2022 Jan 07;8(1):eabh3827
pubmed: 34995117
N Engl J Med. 2022 Mar 31;386(13):1207-1220
pubmed: 35172051
J Cell Physiol. 2021 Dec;236(12):8000-8019
pubmed: 34133758
Nat Rev Immunol. 2020 Oct;20(10):615-632
pubmed: 32887954
Am J Transplant. 2021 Jun;21(6):2290-2297
pubmed: 34085760
Cell Res. 2014 Dec;24(12):1379-80
pubmed: 25412663
Front Cell Infect Microbiol. 2022 Jun 30;12:922422
pubmed: 35846757
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33050983
Thromb Haemost. 2013 Feb;109(2):290-7
pubmed: 23238559
Sci Transl Med. 2022 Jan 26;14(629):eabj5305
pubmed: 34783582
Cell Rep. 2022 Aug 16;40(7):111214
pubmed: 35952673
Front Immunol. 2017 Feb 03;8:47
pubmed: 28220116

Auteurs

Tianyi Zhang (T)

Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Nicholas Magazine (N)

Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Michael C McGee (MC)

Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Mariano Carossino (M)

Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Louisiana Animal Disease Diagnostic Laboratory, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Gianluca Veggiani (G)

Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Konstantin G Kousoulas (KG)

Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.

Avery August (A)

Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.

Weishan Huang (W)

Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.

Classifications MeSH